With more than six million women in
the U.S. affected by infertility issues, IVF centers across the country seek to
help these women conceive and give birth. Unfortunately, it is estimated that
15-30% of the women undergoing infertility evaluation have no cause identified
and are less likely to have a successful IVF experience. According to the
American Society of Reproductive Medicine, endometriosis is associated with up
to 50% of all cases of unexplained infertility.
Current diagnostic techniques for
endometriosis require the use of laparoscopy, an invasive and expensive
surgical procedure. With the introduction of the ReceptivaDx assay,
endometriosis can be identified quickly and cost-effectively using an
endometrial biopsy sample collected during a routine office visit. Early detection of endometriosis can help
guide treatment for IVF centers, ensuring higher success rates and alleviating
the financial and emotional burden of a family attempting to conceive.
“As one of the early adopters of the ReceptivaDx test, our
experience has exceeded my expectations,” said Dr. Aimee Evazzadeh, a reproductive
endocrinologist based in the San Francisco Bay Area. “We can now identify and treat women with
early endometriosis who might have gone undetected before. For our patients, this has led to improved
success rates, reduced costs and the avoidance of multiple IVF cycles.”Over 60,000
babies are born each year as a result of IVF procedures in the U.S. with procedures
failing to achieve success in about half of all cases. The need for a cost-effective test to help
identify endometriosis as a cause for failure is the driver behind the launch
of ReceptivaDx. CiceroDx holds the exclusive license to market and distribute
the test for its use in unexplained infertility.
“ReceptivaDx is a
breakthrough test and provides a unique, enhanced screening opportunity in
women with unexplained infertility and unidentified causes of implantation
failure,” said Bruce Lessey M.D. and Ph.D., a pioneer in reproductive medicine
and related research and a scientific advisor for CiceroDx.
“Our mission at CiceroDx is to ensure we deliver
the most accurate and cost-effective diagnostic tools for doctors and families
looking for answers to unexplained infertility and implantation failure,” said
Chris Jackson, CEO of CiceroDx. “Helping resolve infertility issues is just the
first step. Our goal is to help clinicians better detect endometriosis in the
millions of women who suffer from this silent epidemic every day.”
According to endometriosis.org, an international non-profit group, endometriosis affects an estimated 176 million women worldwide regardless of their ethnic and social background. Many remain undiagnosed and are therefore not treated.
The ReceptivaDx
test for unexplained infertility costs $790 with results available in 3 to 5
days. The test is currently offered in over 75 IVF centers across the U.S.,
Canada, Europe and South America.
For more
information, please visit www.ReceptivaDx.com.
About CiceroDx
CiceroDx is a medical diagnostic company located in Huntington Beach, Calif. ReceptivaDx is the company’s first test panel in the area of unexplained infertility. CiceroDx intends to expand their offering globally and is investing in continued research in the field. For more information, visit http://www.receptivadx.com/about-cicerodx.
CiceroDx is a medical diagnostic company located in Huntington Beach, Calif. ReceptivaDx is the company’s first test panel in the area of unexplained infertility. CiceroDx intends to expand their offering globally and is investing in continued research in the field. For more information, visit http://www.receptivadx.com/about-cicerodx.
No comments:
Post a Comment